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Long-Term Comparison Between Pulmonary Homograft Versus
Bioprosthesis for Pulmonary Valve Replacement in Tetralogy of Fallot
Lucia Cocomello, MD; Marco Meloni, MD; Filippo Rapetto, MD; Mai Baquedano, MSc; Maria Victoria Ordo~nez, MD; Giovanni Biglino, PhD;
Chiara Bucciarelli-Ducci, MD, PhD; Andrew Parry, MD; Serban Stoica, MD; Massimo Caputo, MD
Background-—Tetralogy of Fallot repair results in late occurrence of pulmonary regurgitation, which requires pulmonary valve
replacement in a large proportion of patients. Both homografts and bioprostheses are used for pulmonary valve replacement as
uncertainty remains on which prosthesis should be considered superior. We performed a long-term imaging and clinical
comparison between these 2 strategies.
Methods and Results-—We compared echocardiographic and clinical follow-up data of 209 patients with previous tetralogy of
Fallot repair who underwent pulmonary valve replacement with homograft (n=75) or bioprosthesis (n=134) between 1995 and
2018 at a tertiary hospital. The primary end point was the composite of pulmonary valve replacement reintervention and structural
valve deterioration, deﬁned as a transpulmonary pressure decrease ≥50 mm Hg or pulmonary regurgitation degree of ≥2. Mixed
linear model and Cox regression model were used for comparisons. Echocardiographic follow-up duration was longer in the
homograft group (8 [interquartile range, 4–12] versus 4 [interquartile range, 3–6] years; P<0.001). At the latest echocardiographic
follow-up, homografts showed a signiﬁcantly lower transpulmonary systolic pressure decrease (16 [interquartile range, 12–25] mm
Hg) when compared with bioprostheses (28 [interquartile range, 18–41] mm Hg; mixed model P<0.001) and a similar degree of
pulmonary regurgitation (degree 0-4) (1 [interquartile range, 0–2] versus 2 [interquartile range, 0–2]; mixed model P=0.19). At
9 years, freedom from structural valve deterioration and reintervention was 81.6% (95% CI, 71.5%–91.6%) versus 43.4% (95% CI,
23.6%–63.2%) in the homograft and bioprosthesis groups, respectively (adjusted hazard ratio, 0.27; 95% CI, 0.13–0.55; P<0.001).
Conclusions-—When compared with bioprostheses, pulmonary homografts were associated lower transvalvular gradient during
follow-up and were associated with a signiﬁcantly lower risk of reintervention or structural valve degeneration. ( J Am Heart Assoc.
2019;8:e013654. DOI: 10.1161/JAHA.119.013654.)
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T etralogy of Fallot (TOF) is the most common cyanoticcongenital heart disease, accounting for the 7% to 10%
of all congenital heart disease, with an incidence of 4 to 5 per
10 000 births.1 The surgical repair includes a pulmonary
valvotomy and, depending on the anatomical features, placing a
transannular patch to relieve the right ventricular (RV) outﬂow
tract; and the common sequela of this procedure is pulmonary
valve regurgitation. Pulmonary regurgitation is initially well
tolerated. However, over the years, RV volume overload
leads to RV dilatation and subsequent symptoms of RV
failure, life-threatening arrhythmias, and reduced survival.2,3
Although pulmonary valve replacement (PVR) is the standard
treatment for this condition, controversy still exists about which
prosthesis should be used. Homografts have been considered
as the ﬁrst choice for a long time.4,5 Despite bioprosthesis being
readily available, being easier to be implanted, and having
shown excellent results in the aortic position,6 their durability
for PVR remains controversial.7 Mechanical prostheses are
rarely used because of the increased risk of thrombosis in
pulmonary valve position and patient’s choice.8
Long-term comparisons between homografts and biopros-
thesis are needed to clarify which prosthesis should be
preferred for PVR in patients with TOF.9 Therefore, we
compared long-term results after PVR with pulmonary homo-
grafts versus bioprosthesis using a 20-year single-center
cohort.
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Methods
Because of the sensitive nature of the data collected for this
study, requests to access the data set from qualiﬁed
researchers trained in human subject conﬁdentiality protocols
may be sent to University Hospitals of Bristol at lucia.co-
comello@uhbristol.nhs.uk. The present retrospective analysis
was approved by the audit board at University Hospital of
Bristol, and informed consent was waived. A total of 219
patients with repaired TOF who underwent ﬁrst-time PVR with
either homografts or bioprosthesis valves between 1995 and
2018 at the Bristol Heart Institute were reviewed. The type of
implanted valve was chosen on the basis of the surgeon’s
assessment and homograft availability. Indications for the ﬁrst
PVR intervention were generally pulmonary regurgitation with
symptom or with severe RV dilatation. Patients receiving
mechanical valve (n=1), Contegra valve (n=1), aortic homo-
graft (n=4), and transcatheter valve (n=4) were excluded from
the analysis.
Study End Points
The primary end point was to compare long-term freedom
from PVR reintervention (surgical or transcatheter PVR) or
structural valve degeneration (SVD) in patients receiving
homografts versus bioprostheses. SVD was deﬁned as a
transpulmonary valve systolic pressure decrease ≥50 mm Hg
or signiﬁcant pulmonary regurgitation (3+) at echocardio-
graphic examination.7,10,11 Information about reintervention
and SVD was also obtained from outpatient and inpatient
clinical letters. All-cause mortality was also investigated, and
late mortality was obtained from the Ofﬁce of National
Statistics.
Moreover, existing echocardiographic examination reports
were used to compare echocardiographic measurements in
the homograft and bioprosthesis groups preoperatively, early
(within 1 year) and at the latest follow-up echocardiographic
examination. Velocity across the pulmonary valve was derived
from continuous wave Doppler echocardiography, and peak
systolic pressure gradient was estimated using the modiﬁed
Bernoulli equation. Pulmonary regurgitation was graded into 5
categories: 0, absent; 1, trivial; 2, mild; 3, moderate; and 4,
severe. Finally, to determine the effect of PVR on RV volume
(indexed for body surface area) changes after surgery, data
from available preoperative and follow-up cardiac magnetic
resonance imaging (MRI) examinations were reviewed and
analyzed.
Statistical Analysis
Categorial and continuous variables were presented as
proportion or median and interquartile range, respectively.
Clinical and echocardiographic data of patients treated with
homografts versus bioprostheses were compared using v2
statistics for categorical variables (or the Fisher exact tests
for analyses with a cell count <10) and Wilcoxon rank sum
(Mann–Whitney) test for continuous variables. Kruskal-Wallis
test was used when multiple groups were compared (tableone
R package). To assess the effect of type of prosthesis on
transpulmonary systolic pressure decrease and pulmonary
regurgitation over the time, a mixed linear model for repeated
measurement was used, forcing the interaction term between
treatment and time to follow-up and other risk factors (age,
sex, body mass index, and prosthesis size) as ﬁxed terms and
individual patient as random effect (lme4 R packages). Results
were graphically presented (ggplot2 R package) by plotting
echocardiographic measurements over the time and adding a
smoothed conditional regression line. The same analysis was
used to investigate the effect of time and type of prosthesis
on RV volumes at cardiac MRI examination.
Kaplan-Meier method and log-rank test were used to
compare freedom from the composite of PVR reintervention
and/or SVD in the 2 groups. Multivariable Cox regression
analysis was used to calculate the effect of prothesis type
(homograft versus bioprosthesis) on the risk for PVR reinter-
vention and/or SVD. Competing risk framework was used in
this analysis to account for those patients who died without
primary event (pulmonary valve reintervention/degeneration)
(riskRegression R package). Covariates included in the model
were as follows: age; sex; chromosomal abnormality; smoking
history; left ventricular ejection fraction <50%; body surface
area; concomitant procedures, including tricuspid valve repair,
RV outﬂow tract reconstruction, and pulmonary artery plasty;
time from original repair; and long-term antiplatelet therapy
after surgery (>6 months). Stepwise regression, based on
Akaike information criterion, was used to identify a subset of
variables in the data set, resulting in the best performing
model (lowest prediction error). The same analysis was
repeated to assess the effect of valve choice on mortality.
Clinical Perspective
What Is New?
• Although bioprostheses have become the ﬁrst choice for
pulmonary valve replacement at many centers, we demon-
strated that, in our experience, homografts are associated
with a lower incidence of structural valve degeneration and/
or need for reintervention and lower transvalvular gradient.
What Are the Clinical Implications?
• Homografts should be considered as a ﬁrst choice in
patients undergoing pulmonary valve replacement.
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The following variables were tested as treatment effect
modiﬁers on the primary outcome by subgroup analysis and
interaction term: age (≤10, 11–19, and ≥20 years), long-term
antiplatelet therapy (>6 months), and different eras (1995–
2009 versus 2010–2018). An a of 0.05 was used as the
cutoff for signiﬁcance. All statistical analyses were performed
using R Statistical Software, version 3.2.3 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
The study population consisted of 209 patients with previous
TOF repair who underwent PVR with homograft (n=75) or
bioprosthesis (n=134) between 1995 and 2018. From 1995
to 2006, homografts only were used, whereas bioprostheses
became the preferred choice more recently (Figure 1). The
most frequently used bioprosthetic valves were Perimount
valve (n=56) and Hancock Medtronic (n=62), whereas Matrix
(n=13), St Jude Epic (n=1), and Shelhigh (n=2) valves were
used in remaining cases. Demographic and operative data and
medication at discharge in the 2 groups are summarized in
Table 1. Patients receiving homografts were more likely to
present a smaller body surface area, a lower incidence of
concomitant tricuspid valve repair, and a shorter time from
initial repair to PVR.
Echocardiographic Findings
Preoperative, early, and latest follow-up echocardiographic
examination ﬁndings are reported in Table 2. Echocardio-
graphic follow-up duration was longer in the homograft group
(8 [interquartile range, 4–12] versus 4 [interquartile range, 3–
6] years; P<0.001). At the latest follow-up, transpulmonary
systolic pressure decrease was signiﬁcantly lower in the
homograft group (16 [interquartile range, 11.56–25.52] ver-
sus 28 [interquartile range, 18.12–40.75] mm Hg; P<0.001),
despite a longer follow-up duration in the homograft group.
Homografts showed a statistically signiﬁcant, but not clinically
relevant, higher pulmonary regurgitation degree at early
follow-up, but this difference was no longer present at latest
follow-up. Mixed models (Table 3, Figure 2) for repeated
measurement showed that homografts were independently
associated with a signiﬁcantly lower transpulmonary systolic
pressure decrease (8.92.5 mm Hg; P<0.001) and a
comparable degree of pulmonary regurgitation (0.2°0.2°;
P=0.19) when compared with bioprostheses. Prosthesis size
was negatively associated with systolic pulmonary pressure
decrease, but we found no signiﬁcant interaction between the
effect of homograft and prosthesis size (P=0.11; Figure S1).
Other predictors of increased transpulmonary systolic pres-
sure decrease were a longer duration of follow-up and a larger
body surface area. Male sex was associated with a marginally
nonsigniﬁcant increased transpulmonary pressured decrease.
When the analysis was stratiﬁed according to the type of
bioprosthesis used (Tables S1 and S2), we found that
Hancock (33 [interquartile range, 19–42] mm Hg; P<0.001)
and other types of bioprostheses (44 [interquartile range, 30–Figure 1. Number of bioprostheses and homografts per year.
Table 1. Baseline Characteristics in Patients Receiving
Homograft Versus Bioprosthesis
Characteristics Homograft Bioprosthesis P Value
No. 75 134 . . .
Age, median (IQR), y 23 (12–35) 24 (18–34) 0.16
Male, n (%) 40 (53.3) 78 (58.2) 0.59
Chromosomal
abnormality, n (%)
6 (8.0) 17 (12.7) 0.42
Smoking history, n (%) 14 (18.7) 26 (19.4) 1.0
LVEF <50%, n (%) 8 (10.7) 24 (17.9) 0.23
BSA, mean (SD), m2 1.59 (0.44) 1.72 (0.30) 0.02
Concomitant TVR, n (%) 3 (4.0) 21 (15.7) 0.02
Concomitant RVOT
reconstruction, n (%)
10 (13.3) 15 (11.2) 0.81
Concomitant PA
plasty, n (%)
16 (21.3) 29 (21.6) 1.0
Time from repair,
median (IQR), y
20 (12–27) 22 (16–31) 0.02
Long-term antiplatelet
therapy, n (%)
31 (41.3) 55 (41.0) 1
BSA indicates body surface area; IQR, interquartile range; LVEF, left ventricular ejection
fraction; PA, pulmonary artery; RVOT, right ventricular outﬂow tract; TVR, tricuspid valve
repair.
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57] mm Hg; P<0.001) but not Perimount (25 [interquartile
range, 17–32] mm Hg; P=0.15) were associated with a
signiﬁcantly increased transpulmonary systolic pressure
decrease over time when compared with homografts (16 [in-
terquartile range, 12–26] mm Hg). On the other hand,
Hancock valves were associated with 0.5 reduction in the
pulmonary regurgitation degree (0.50.2 mm Hg; P=0.005)
when compared with homografts (Figure S2).
Primary End Point Analysis
After a median follow-up time of 10 (interquartile range, 5–13)
and 4 (interquartile range, 2–7) years for patients treated with
homograft and bioprosthesis, respectively, a total of 11
homografts (3 endocarditis and 8 SVD) and 11 bioprostheses
(2 endocarditis and 9 SVD) required reintervention. Overall,
SVD was observed in 10 and 25 homografts and bioprosthe-
ses, respectively. Freedom from SVD/reinvervention on the
pulmonary valve at 3, 5, and 9 years was 95.7% (95% CI,
91.0%–100.0%) versus 87.2% (95% CI, 80.8%–93.5%), 89.5%
(95% CI, 82.2%–96.9%) versus 79.0% (95% CI, 70.1%–88.0%),
and 81.6% (95% CI, 71.5%–91.6%) versus 43.4% (95% CI,
23.6%–63.2%) in the homograft and bioprosthesis groups,
respectively (log-rank P=0.002; Figure 3). After adjusting for
other risk factors, pulmonary homografts were an indepen-
dent predictor of freedom from reintervention/SVD (ad-
justed hazard ratio [HR], 0.27; 95% CI, 0.13–0.55; P<0.001;
Table S3). Homografts were superior to bioprostheses
regardless of patient age (interaction P=0.61), although
the beneﬁt from homografts was larger in patients aged
between 11 and 19 years (HR, 0.15; 95% CI, 0.02–1.2) and
≥20 years (HR, 0.32; 95% CI, 0.13–0.77) than in patients
aged ≤10 years (HR, 0.81; 95% CI, 0.08–8.13) (Figure S3).
Homografts were superior to bioprostheses in patients with
(HR, 0.14; 95% CI, 0.02–1.23) and without (HR, 0.40; 95%
CI, 0.19–0.85) long-term antiplatelet therapy (interaction
P=0.76). However, the use of long-term antiplatelet therapy
was associated with a lower risk of SVD/reintervention in
the overall population (HR, 0.28; 95% CI, 0.13–0.64;
P=0.002) and in patients who received homograft (HR,
0.23; 95% CI, 0.05–0.99; P=0.04) and bioprosthesis (HR,
0.30; 95% CI, 0.12–0.8; P=0.02; Figure S4). The effect of
homograft was not signiﬁcantly inﬂuenced by eras of
surgery (P=0.77). When compared with homografts, Han-
cock and other valves were signiﬁcantly associated with a
signiﬁcantly increased risk of reintervention/SVD, whereas
Perimount valves were associated with a nonsigniﬁcant
increased risk (Table S4, Figure S5). No hospital death was
recorded. Overall survival rates at 9 years were 90.6% (95%
CI, 83.4%–97.9%) versus 99.2% (95% CI, 97.8%–100.0%) in
the homograft and bioprosthesis groups, respectively, with
no signiﬁcant difference between the 2 groups after
multivariate adjustment (log-rank test P=0.08; adjusted
P=0.14).
Table 2. Echocardiographic Data at Baseline, at 1-Year
Follow-Up, and at Latest Follow-Up
Variable Homograft Bioprosthesis P Value
Preoperative data
No. 75 134 . . .
TV regurgitation degree (0–4) 2 (1–2) 2 (1–2) 0.95
TV regurgitation pressure
decrease, mm Hg
39 (31–62) 30 (25–42) 0.003
PV regurgitation degree (0–4) 4 (3–4) 4 (3–4) 0.08
PV systolic pressure
decrease, mm Hg
24 (16–38) 19 (14–31) 0.12
Early follow-up data (within 1 y)
No. 65 129 . . .
TV regurgitation degree (0–4) 1 (1–2) 1 (1–2) 0.50
TV regurgitation pressure
decrease, mm Hg
39 (31–62) 29 (21–36) 0.62
PV regurgitation degree (0–4) 1 (0–2) 0 (0–1) <0.001
PV systolic pressure
decrease, mm Hg
18 (12–27) 22 (16–31) 0.01
Latest follow-up available data
No. 48 87 . . .
Follow-up duration, y 8 (4–12) 4 (3–6) <0.001
TV regurgitation degree (0–4) 1 (1–2) 1 (1–2) 0.96
TV regurgitation pressure
decrease, mm Hg
30 (25–41) 32 (25–45) 0.23
PV regurgitation degree (0–4) 1 (0–2) 2 (0–2) 0.52
PV systolic pressure
decrease, mm Hg
16 (12–25) 28 (18–41) <0.001
Data are presented as median (interquartile range). PV indicates pulmonary valve; TV,
tricuspid valve.
Table 3. Risk Factors for Trans-PPD and PVR (0°–4°) After
Pulmonary Valve Replacement (Mixed Linear Model for
Repeated Measurement)
Risk Factors
End Point
PPD, mm Hg P Value PVR, ° P Value
Homograft 8.92.5 <0.001 0.20.2 0.19
Follow-up duration 1.10.3 0.001 0.1.02 <0.001
Valve size 1.90.7 0.006 0.020.05 0.61
Age 0.10.1 0.21 0.010.006 0.01
Body surface area 11.83.6 0.001 0.250.25 0.31
Male 3.41.8 0.06 0.040.13 0.74
Homograft/time 1.00.4 0.02 0.080.03 0.02
PPD indicates pulmonary systolic pressure decrease; PVR, pulmonary valve regurgitation.
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Cardiac MRI Findings
Cardiac MRI ﬁndings are summarized in Table 4. A total of 21
and 85 patients with homograft and bioprosthesis, respec-
tively, underwent baseline cardiac MRI. Of those patients, 17
and 40, respectively, underwent cardiac MRI follow-up; and 9
and 16, respectively, among those had late cardiac MRI
follow-up. We observed a signiﬁcant reduction of indexed end-
diastolic and end-systolic RV volumes in both patients treated
with homografts or bioprostheses, with no signiﬁcant differ-
ence between the 2 groups. Repeated measures mixed model
conﬁrmed that type of prosthesis (homograft versus biopros-
thesis) did not signiﬁcantly inﬂuence the reduction in RV
volumes (indexed end-diastolic RV volume, 8.57.8 mL/m2
[P=0.27]; indexed end-systolic RV volume, 3.15.1 mL/m2
[P=0.53]; Figure 4).
Discussion
Little published data are available directly comparing the
performance of bioprosthetic valves with homografts in the
pulmonary position, with conﬂicting ﬁndings reported.7,11–13
The present long-term follow-up study following PVR with
homografts versus bioprostheses in patients previously
treated for TOF found that pulmonary homografts were
associated with lower transvalvular gradients and lower
incidence of SVD and need for reintervention. This effect
was more pronounced among patients aged >10 years,
although the number of patients aged ≤10 years was small to
draw conclusion.
Both strategies achieved signiﬁcant reduction in RV
volumes, as shown by cardiac MRI examination. Among
bioprostheses, Perimount was associated with a lower
Figure 2. Postoperative changes in transpulmonary systolic pressure decrease (left) and pulmonary valve regurgitation degree (right) at
echocardiographic examinations in patients treated with homografts and with bioprotheses.
Figure 3. Freedom from structural valve deterioration (SVD)/
reintervention in patients treated with homografts and with
bioprotheses.
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transvalvular gradient and a lower incidence of SVD and need
for reintervention. Similar degrees of pulmonary regurgitation
with homografts and bioprostheses were observed at late
follow-up.
To our knowledge, this is the largest comparison of
echocardiographic, cardiac MRI, and clinical outcomes
between pulmonary homografts and bioprostheses. In a
previously published small series, Fiore et al11 compared 15
homografts with 18 bovine pericardial and 49 porcine stented
bioprostheses. They reported no signiﬁcant differences
between the 3 groups in terms of transpulmonary valve
gradients and a signiﬁcantly higher incidence of valve
dysfunction with homografts (54%) when compared with
bovine pericardial valves (5.5%) and porcine valves (19%).
However, it is not possible to draw a deﬁnitive conclusion
from this report because of the small number of patients
receiving homografts.
Batlivala et al12 reported on 84 cryopreserved homografts
and 170 bioprosthetic valves. At 10 years, freedom from
moderate or severe pulmonary regurgitation was 61% and
freedom from moderate or severe stenosis was 74%, with no
difference between the 2 cohorts. However, the homograft
group in this study contained 50 aortic homografts, which
have previously been shown to deteriorate more rapidly in the
pulmonary position.14 The only 4 aortic homografts in our
study population were intentionally excluded from the ﬁnal
analysis.
Zubairi et al13 compared the performance of 56 cryopre-
served pulmonary homografts with 113 bioprosthetic valves.
No difference in reoperation was observed between the 2
groups, with freedom of reoperation of 93% at 5 years and
71% at 10 years. However, a higher proportion of children
aged <10 years received a homograft and younger age
(<3 years) was identiﬁed as a risk factor for homograft failure.
Our ﬁndings are supported by another report by Bell et al7
on patients aged 10 to 20 years, who presented freedom from
SVD at 10 years in 85% and 53% with homografts (n=131)
and bioprostheses (n=57), respectively. Bioprostheses were
associated with a 5-fold increase in risk of SVD when
compared with homografts (HR, 5.64; 95% CI, 2.11–15.07;
P<0.001). Subgroup analysis demonstrated no statistical
difference in the performance of bovine and porcine biopros-
theses, despite a trend toward better performance of the
bovine bioprosthesis.
We found that homografts provided lower transvalvular
gradients regardless of the annulus size, and it has been
proposed that improved RV outﬂow tract hemodynamic
conditions contribute to the beneﬁcial effect of homografts.
Von Knobelsdorff-Brenkenhoff et al15 described variable ﬂow
hemodynamic outcomes after aortic valve replacement using
mechanical, stented, or nonstented xenografts. Additional
studies focused on comparison of the ﬂow hemodynamics
after aortic root replacement either with a mechanical valved
conduit or by applying the valve-sparing techniques.16–18 Both
studies concluded that valve-sparing techniques improved
ﬂow hemodynamic parameters compared with xenograft valve
conduits, which could potentially lead to reduced stress and
deterioration of the morphologically normal trileaﬂet valve,
compared with a xenograft. Unfortunately, no 4-dimensional
ﬂow MRI data are available for assessing RV outﬂow tract ﬂow
Table 4. Cardiac MRI Findings in Patients Treated With Homograft Versus Bioprosthesis and Results of Mixed Model
Variable Homograft Bioprosthesis P Value
Preoperative data
No. 21 85 . . .
Indexed RV EDV, mL/m2 150 (119–164) 150 (135–169) 0.33
Indexed RV ESV, mL/m2 76 (62–90) 74 (61–88) 0.91
Follow-up MRI data
No. 17 40 . . .
Follow-up duration, y 4.7 (2.4–8.9) 2.1 (1.2–4.4) 0.045
Indexed RV EDV, mL/m2 104 (87–112) 106 (84–131) 0.08
Indexed RV ESV, mL/m2 53 (42–59) 53 (38–74) 0.21
Late follow-up MRI data
No. 9 16 . . .
Follow-up duration, y 7.9 (7.3–8.8) 6.5 (5.0–8.2) 0.14
Indexed RV EDV, mL/m2 107 (98–112.25) 114 (95–131) 0.57
Indexed RV ESV, mL/m2 58 (52–75) 59 (43–74) 0.61
Data are presented as median (interquartile range). MRI indicates magnetic resonance imaging; EDV, end-diastolic volume; ESV, end-systolic volume; RV, right ventricular.
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dynamics with different pulmonary valve prosthesis. Studies
using imaging techniques, such as 4-dimensional cardiac MRI,
are beginning to shed light on the hemodynamics in patients
with TOF. Using this technique, it has been observed that
patients with repaired TOF and pulmonary regurgitation
presented with misaligned hemodynamic forces in the left
ventricle and higher diastolic RV forces along the direction of
regurgitant ﬂow, compared with healthy controls.19 Changes
in kinetic energy and intracardiac vorticity have also been
observed in patients with TOF using 4-dimensional cardiac
MRI, suggesting the potential for a novel noninvasive
biomarker.20–22 A recent case report suggests the role for
4-dimensional cardiac MRI in assessing patients with TOF
before and after valve replacement,23 yet data on RV outﬂow
tract ﬂow dynamics with different pulmonary valve prostheses
are still lacking.
Finally, we have found that long-term antiplatelet therapy
was associated with a signiﬁcantly lower risk of SVD and
reintervention regardless the type of valve used and, there-
fore, this treatment should be strongly recommended after
PVR unless contraindication exists.
Limitations
The main limitation of our analysis is its observational nature.
Despite the fact that we used multivariable adjustment, other
unmeasured factors not included in the model can have
inﬂuenced our results. Second, patients receiving a biopros-
thesis were more likely to have had their operations recently
when compared with those receiving homografts, resulting in
unequal follow-up times and cohort effects by which patients
receiving a bioprosthesis were likely to beneﬁt from more
recent advances in surgical and medical technologies. We
have used a mixed model to account for difference in follow-
up duration, and estimates were unchanged. Furthermore,
this potential bias is likely to have favored the bioprosthesis
group and, therefore, to have attenuated our effect estimates,
thus supporting our ﬁnal conclusions. It is suggested that
velocity propagation may differ between homografts and
bioprostheses, and a lower cutoff for SVD has been suggest
for homografts.24 However, the value of a lower threshold for
homografts has not been clinically validated; and a peak
gradient of 50 mm Hg is still widely regarded as the cutoff for
surgical reintervention, regardless of type of prosthesis.7,10,11
Finally, we found an excess of deaths in the homograft group,
which was not statistically signiﬁcant after multivariable
adjustment. Moreover, the present analysis is largely under-
powered to detect a difference in survival.
Conclusions
The present ﬁndings suggest that pulmonary homografts
outperformed bioprosthetic valves when implanted in the
pulmonary position in patients with pulmonary regurgitation
Figure 4. Postoperative changes in right ventricle (RV) end-diastolic (left) and end-systolic (right) volume at cardiac magnetic resonance
imaging examinations in patients treated with homografts and with bioprotheses.
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with previous TOF repair, with a larger effect in patients aged
≥10 years. On the basis of this observation, pulmonary
homografts may be considered as ﬁrst choice in this
population. However, other factors should be considered in
the choice of prosthesis, including the conundrum with
availability of good quality homografts and the role of the
transcatheter, within previous failed PVR.25
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Table S1. Baseline characteristics in patients receiving homograft vs different types of 
bioprosthesis. 
 Hancock Homograft Other Perimount P-value 
n  62 75 16 56  
Age, years (median (IQR)) 26[19-36] 23 [12-35] 28[24-37] 20 [17-31] 0.04 
Male n(%) 41 (66.1) 40 (53.3) 7 (43.8) 30 (53.6) 0.27 
Chromosomal abnormality n(%) 4 ( 6.5) 6 ( 8.0) 4 (25.0) 9 (16.1) 0.08 
Smoking history n(%) 14 (22.6) 14 (18.7) 2 (12.5) 10 (17.9) 0.80 
LVEF<50%  12 (19.4)    8 (10.7)    1 (6.2)   11 (19.6) 0.28 
BSA, m2 (mean (SD))  1.78 (0.29) 1.59 (0.44) 1.70 (0.33) 1.65 (0.29) 0.02 
Concomitant TVR n(%) 16 (25.8) 3 ( 4.0) 1 ( 6.2) 4 ( 7.1) <0.001 
Concomitant RVOT reconstruction 
n(%) 
10 (16.1) 10 (13.3) 1 ( 6.2) 4 ( 7.1) 0.41 
Concomitant PA plasty n(%) 12 (19.4) 16 (21.3) 2 (12.5) 15 (26.8) 0.60 
Time from repair (median (IQR)) 23.9[18.6-33] 19.75[11.9-26.9] 24.4[20.4-33.1] 18.7[14.7-26.4] 0.005 
Long-term antiplatelet therapy n(%) 25 (40.3) 31 (41.3) 4 (25.0) 26 (46.4) 0.50 
BSA: body surface area; TVR: tricuspid valve repair; RVOT right ventricular outflow tract; 
PA: pulmonary artery   
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Table S2. Echocardiographic data at 1 year follow-up and at latest follow-up in patients receiving Homograft vs different types of 
bioprosthesis. 
   Hancock Homograft Other Perimount P-value 
1-year follow-up      
n  61 65 15 53  
TV regurgitation degree (0-4) 1 [1-2] 1 [1-2] 2 [1-2] 1 [1-2] 0.48 
TV regurgitation pressure drop (mmHg)  29[25-43] 39[31-62] 31 [26 -39] 31 [27-37] 0.72 
PV regurgitation degree (0-4) 0 [0-0] 1 [0-2] 1 [0-2] 1 [0-2] <0.001 
PV systolic pressure drop (mmHg) 29 [21-34] 18 [12-27] 22 [12-31] 17 [14-22] <0.001 
Latest follow-up available       
N 31 48 14 42  
 follow-up duration (years) 4 [1-5] 7 [4-12] 7 [4-8] 4 [3-6] <0.001 
TV regurgitation degree (0-4) 1 [1-2] 1 [1-2] 2 [1-2] 2 [1-2] 0.80 
TV regurgitation pressure drop (mmHg) 31 [21-43] 30 [25-41] 47 [36-52] 32 [26-36] 0.03 
PV regurgitation degree (0-4) 1 [0-2] 1 [0-2] 2 [1-3] 2 [1-2] 0.10 
PV systolic pressure drop (mmHg) 33 [19-42] 16 [12-26] 43.56 [30-57] 25 [17-32] <0.001 
 
Data are presented as median and inter-quantile range; TV: tricuspid valve; PV: pulmonary valve 
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Table S3. Risk factors for structural valve deterioration (SVD)/reintervention of the 
pulmonary valve substitute (prosthesis type as Homograft vs bioprosthesis) identified 
by Cox regression model.  
                  Variable   Hazar Ratio         95%CI     p-value  
Homograft (bioprosthesis as ref)          0.27   [0.13;0.55]     < 0.001  
Age (per 1-year increase)          0.96   [0.93;1.00]     0.055 
male sex          2.07   [1.06;4.03]     0.03  
BSA          0.36   [0.12;1.03]     0.06  
Concomitant TVR          0.18   [0.04;0.93]     0.04  
    Long-term antiplatelet therapy          0.28   [0.12;0.63]     0.002  
CI: confidence interval; BSA: body surface area; TVR: tricuspid valve repair 
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Table S4. Risk factors for structural valve deterioration (SVD)/reintervention of the 
pulmonary valve substitute including different types of bioprostheses identified by Cox 
regression model. 
                          Variable       Units   Hazard Ratio  95%CI    p-value  
  Type of valve   Homograft           Ref                             
                                       Hancock          4.26   [1.74;10.45]     0.001 
                                         other          8.20   [3.19;21.12]     < 0.001  
                                     Perimount          2.03    [0.80;5.18]     0.13  
Age (per 1-year increase)                     0.95    [0.91;0.99]     0.016  
male sex                      2.20    [1.09;4.43]     0.02  
BSA                      0.37    [0.13;1.07]     0.07  
Concomitant TVR                      0.10    [0.02;0.58]     0.01  
    Long-term antiplatelet therapy                      0.31    [0.14;0.71]     0.005  
CI: confidence interval; BSA: body surface area; TVR: tricuspid valve repair 
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Figure S1. Relationship between trans-pulmonary systolic pressure drop over the time patients receiving homografts and bio-protheses 
stratified by prosthesis size.  
D
ow
nloaded from
 http://ahajournals.org by on January 16, 2020
  
Figure S2. Relationship between trans-pulmonary systolic pressure drop (left) and pulmonary regurgitation degree (right) over the time 
patients receiving homografts and different type of bio-protheses. 
     
D
ow
nloaded from
 http://ahajournals.org by on January 16, 2020
  
Figure S3. Freedom from structural valve deterioration (SVD)/reintervention in patients receiving homografts vs bioprostheses 
stratified by age.  
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Figure S4. Freedom from structural valve deterioration (SVD)/reintervention in patients receiving homografts vs bioprostheses 
stratified by long term (>6 months) antiplatelet therapy following surgery.  
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Figure S5. Freedom from structural valve deterioration (SVD)/reintervention in 
patients receiving homografts vs bioprostheses stratified by eras of surgery. 
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